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Inherited factor VII deficiency (FVIID) is the most
common ‘rare’ bleeding disorder and is characterized
by a variable bleeding tendency. A subgroup of
patients with FVIID present with a severe clinical
bleeding phenotype characterized by spontaneous
bleeding in early infancy [1]. Surgery in such patients
carries a risk of bleeding and the optimal treatment
regimen for major surgeries has still not been defined.
Continuous infusion of rFVIIa (CI-rFVIIa) has been
used most commonly during orthopaedic surgery with
good outcomes; however, experience with CI-rFVIIa is
limited, with very few data on comparisons between
bolus and continuous infusion regimens [2].
We present a patient with severe FVIID (FVII
activity < 1 IU mL1) with intractable atonic (drop)
seizures attributed to a spontaneous intracranial haem-
orrhage (ICH) in the neonatal period who underwent a
total corpus callosotomy for control of seizures. Preop-
eratively, we administered rFVIIa in three dosing regi-
mens so as to enable us to choose the optimal regimen
for use during and after his planned major neurosurgi-
cal procedure. Preoperatively, we monitored tissue
factor thromboelastographic (TF-TEG) parameters,
prothrombin time (PT) and FVII activity after the three
rFVIIa doses. Eventually, we chose one dosing regimen
for use during surgery and the patient successfully
underwent the surgery with no bleeding complications
and had an excellent outcome.
The patient is an 8-year-old male of Middle Eastern
origin who was diagnosed with severe FVIID in the
neonatal period. He developed a right-hemispheric
ICH at 24 days of age. At approximately seven and a
half years of age, he developed recurrent seizures con-
sisting of sudden drops that were precipitated by
unanticipated auditory stimuli. These gradually
increased in frequency from 2 per day to 20 per day
and the seizures were resistant to different antiepilep-
tic medications. Due to the seizures, the patient
sustained multiple falls and developed recurrent
musculo-skeletal bleeding episodes. Due to the risk for
secondary haemorrhage as well as the negative impact
on his quality of life, surgical options were explored.
Vagal nerve stimulation (VNS), corpus callosotomy or
a right hemispherectomy was considered for control-
ling his seizures. The major disadvantage of hemi-
spherectomy was potential catastrophic bleeding while
that of VNS was that rarely does this abolish all sei-
zure episodes. A more conservative surgery (i.e. total
corpus callosotomy) was considered to be the most
reasonable option, offering an 80% chance of total
seizure control in atonic (drop) seizures.
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Preoperatively, the patient electively received three
different dosing treatments with rFVIIa (NovoSeven
RT; Novo Nordisk A/S, Bagsvaerd, Denmark) on three
separate days: (i) 1 mg bolus (27 lg kg1, low-dose
bolus, LDB-rFVIIa), (ii) 2 mg bolus (54 lg kg1, high-
dose bolus, HDB-rFVIIa) and (iii) continuous infusion
rFVIIa (CI-rFVIIa). Continuous infusion dose was
administered as follows. The patient received a bolus of
0.3 mg (8 lg kg1) followed by a continuous infusion of
1.7 mg over the next 5 h (~9 lg kg1 h1). Due to
the small volume of reconstituted rFVIIa, 1.7 mg of
rFVIIa was diluted in 15 mL of normal saline and
infused at 3 mL h1.
As he was on secondary prophylaxis with rFVIIa,
the prophylactic dose was held on the day of testing to
allow for a washout interval of at least 24 h. The
rFVIIa was infused via a tunnelled central venous cath-
eter and all samples were collected via a peripheral
venous draw. Samples were collected for PT, FVII
activity and TF-TEG at baseline (pre-rFVIIa) and at 1,
2, 4 and 6 h after the bolus doses. For CI-rFVIIa, sam-
ples were drawn at baseline and at 15 min and at 1,
2 and 4 h. Factor VII activity was tested in citrated
plasma (3.2%) using a one-stage mechanical clotting
assay on the STA-R Evolution (Diagnostica Stago,
Parsippany, NJ, USA). The assay utilized a calcium
thromboplastin from rabbit cerebral tissues (Neoplas-
tine CI; Diagnostica Stago) with human factor VII-
deficient plasma (George King Bio-Medical, Inc.
Overland Park, KS, USA) to measure the clotting
time vs. the standard plasma (STA Unicalibrator;
Diagnostica Stago). TF-TEG was performed as per a
published method [3]. The results are documented in
Table 1 and Fig. 1.
As the PT, FVII and TEG parameters were most
stable after CI- rFVIIa, a decision was made to use
this regimen for surgery. The patient received
CI-rFVIIa as described above (the bolus dose was
given just prior to surgery followed by continuous
infusion during and after surgery). The patient
underwent the surgery with an estimated blood loss
of 50 mL. We were able to decrease his CI-rFVIIa
further on postoperative days 2 (7 lg k1 h1) and
3 (4.5 lg k1 h1) as his PT, FVII activity and TF-
TEG were in the acceptable range with no bleeding
(Table 2). The continuous infusion was stopped on
postoperative day 8 and the patient was discharged
home on prophylactic rFVIIa regimen (home regi-
men). The patient has been seizure free for more
than 9 months after surgery and continues on sec-
ondary rFVIIa prophylaxis (2 mg rFVIIa every other
day) for prevention of recurrent ICH.
Congenital severe FVII deficiency (FVIID) is a rare
bleeding disorder characterized by broad clinical
heterogeneity. Replacement of FVII by giving
plasma-derived FVII, rFVIIa, fresh frozen plasma or
prothrombin complexes remains the treatment of T
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choice for patients with bleeding and for those under-
going surgery [4]. Bleeding from surgical procedures
has been reported in one-third of the patients with
FVIID and risk of bleeding varies with the type of sur-
gery, tissue or organ involvement and the type of
anaesthesia [5]. Previous reports of bolus doses ranging
from 15 to 90 lg kg1 have been used in patients at
an interval of 4–6 h [6]. Such regimens, however, lead
to wide fluctuations in the FVIIa activity with supra-
therapeutic levels after the bolus doses and sub-thera-
peutic levels by hour 4 [7]. Factor VII replacement
after surgery has also been associated with the devel-
opment of an inhibitor and thrombotic complications
[4,8].
Recently, an analysis from the Seven Treatment
Evaluation Registry for surgical procedures was pub-
lished in which surgeries were classified as either major
(open abdominal, orthopaedic, cardiovascular or neu-
rosurgery) or minor [5]. Of the 41 elective surgeries in
34 patients, only three patients received continuous
infusions. There were seven patients with FVII level of
<1% but none had central nervous system bleeding
and presumably did not undergo a neurosurgical pro-
cedure. The minimally effective dose was deemed to be
13 lg kg1 body weight with two additional doses.
This supports the concept proposed by other research-
ers that in FVIID patients, a lower dose of FVIIa may
be needed for achieving haemostasis [9]. Given the
wide fluctuations in FVII levels obtained with bolus
dosing and the risk of inhibitor formation or thrombo-
sis with such dosing regimens, we felt that low-dose CI
rFVII was the optimal regimen for our patient.
There is no consensus regarding the dose or rate of
continuous infusion of rFVIIa. Schulman et al. reported
bolus doses in their study ranging from 4 to 66 lg kg1
followed by continuous infusion with variable doses
[6]. A publication by Tran et al. reported the effective
use of CI-rFVIIa in 13 major surgeries out of 25 surgical
procedures, all of which were non-central nervous sys-
tem surgeries [2]. They used a bolus dose of
8.5 lg kg1 followed by a rate of 0.9 lg kg1 h1
along with tranexamic acid and reported a significant
reduction in use of medication usage and cost.
In our patient, we were able to compare three dos-
ing regimens prior to a major elective neurosurgical
procedure. After LD-bolus dose, the PT was found to
be prolonged after 4 h. Conversely, several of the
samples after HDB-rFVIIa were clotted, suggesting
extremely high levels of FVII. An analysis of labora-
tory measurements (PT, FVII levels and TEG),
revealed low dose continuous infusion to be superior
to bolus doses. This regimen was subsequently chosen
for the surgery. Due to a possible additional risk of
thrombosis with tranexamic acid, we chose to elimi-
nate the use of tranexamic acid (as described previ-
ously by Tran et al.) but chose to give a higher dose
of continuous infusion of rFVIIa [2]. Once surgical
haemostasis was achieved, we were able to rapidly
wean the CI-rFVIIa dose on days 2 and 3 postopera-
tively with normalization of haemostatic parameters.
To our knowledge, this is the first study that has
compared three different dosing regimens prior to an
elective major neurosurgical procedure. We found that
(a)
(b)
Fig. 1. Sequential changes in prothrombin time (PT) and factor VII activ-
ity (refer Table 1 for actual numbers).
Table 2. Intra- and postoperative management of continuous infusion of rFVIIa.
Preoperative Intraoperative Postoperative day 1 Postoperative day 2 Postoperative days 3–7
Bolus dose 0.3 mg (8 lg kg1) NA NA NA NA
Continuous
infusion (lg kg1)
1.7 mg/5 h (9 lg kg1 h1) 2 mg/6 h
(9 lg kg1 h1)
2 mg/6h
(9 lg kg1 h1)
2 mg/8 h
(7 lg kg1 h1)
2 mg/12 h
(4.5 lg kg1 h1)
PT Not done as baseline levels available
from preoperative testing (Table 1)
9.4 s 9.1 s 10 s 9.4–9.9 s
FVII activity Not done as baseline levels available
from preoperative testing (Table 1)
361% 361% 291% 285–311%
R time TF-TEG Not done as baseline
levels available from before
Short R time Short R time Short R time Normal R time
Outcomes and
interventions
Start CI-rFVIIa Continue CI-rFVIIa;
no bleeding
Decrease CI-rFVIIa;
no bleeding
Decrease CI-rFVIIa;
no bleeding
Continue CI-rFVIIa;
no bleeding
PT, prothrombin time; CI, continuous infusion; rFVIIa, recombinant factor VIIa.
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continuous infusion rFVIIa was superior to bolus
rVIIa regimens in terms of better maintenance of
steady coagulation parameters and cost-effectiveness.
Low-dose continuous infusion rFVIIa may be the opti-
mal way to manage surgical procedures, especially
major procedures in patients with severe FVIID.
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High titre inhibitor to factor VIII in a haemophilia carrier
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Several aspects of mild haemophilia, defined as factor
VIII coagulant activity (FVIII:C) between 0.05 and
0.40 IU mL1, are currently under investigation. One
is inhibitor development and treatment. Patients with
mild haemophilia have been recognized as a low-risk
group, with an overall incidence estimated between
3% and 13%. Despite the lower risk of appearance
compared with severe haemophilia, inhibitor can be
an important clinical challenge regarding management
of bleeding and eradication. It has been demonstrated
that an intensive exposure to FVIII, mainly in a surgi-
cal setting, predisposes to inhibitor appearance, the
risk being higher in carriers of the Arg593Cys mis-
sense mutation in the F8 gene. This mutation, for
instance, modifies FVIII three-dimensional structure
since cysteine is ought to form disulphide bridges [1].
In haemophilia carriers, one of the two X-chromo-
somes is inactivated during embryonic life [2]. Indeed
FVIII levels may range widely because lyonization is
not always random. Abnormalities in the initial choice
of X-chromosome inactivation have been reported in
haemophilia carriers with bleeding symptoms and
FVIII levels far below 0.50 IU mL1 [3]. Carriers with
low FVIII levels can bleed resembling the clinical pic-
ture of mild haemophilia [4]. Bleeding haemophilia
carriers sometimes need replacement therapy, typically
in major surgical procedures where desmopressin may
not ensure sufficiently prolonged high levels of FVIII.
To the best of our knowledge, only one case of spon-
taneous inhibitor occurrence has been reported so far
in a female carrier of haemophilia [5].
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